Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments$4,995
- February- 2016
- In Pharmaceuticals
- By GBI Research 826 Views
Parkinson’s Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson’s Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer’s disease it is the second most common ……….
Total Pages: 136